• <em>CACNA1A</em> Gene Variants in Eight Chinese Patients With a Wide Range of Phenotypes
• <em>CACNA1A</em> Mutations Associated With Epilepsies and Their Molecular Sub-Regional Implications
• <em>TRPM7</em> as a Candidate Gene for Vestibular Migraine
• 36-year-old Male with Syncope
• A - 49 Neuropsychological and Clinical Features of Ataxia Due to CACNA1A (P.1661H) Mutation: a Case Study
• A De Novo HECW2 Variant in a Patient with Acetazolamide-Responsive Episodic Ataxia
• A neurodevelopmental disorder caused by a dysfunctional <em>CACNA1A</em> allele
• A novel CACNA1A mutation associated with episodic ataxia 2 presenting with periodic paralysis
• A Novel CACNA1A Nonsense Variant [c.4054C>T (p.Arg1352(*))] Causing Episodic Ataxia Type 2
• A Novel Frameshift CACNA1A Mutation Causing Episodic Ataxia Type 2
• A novel mutation in CACNA1A gene in a Saudi female with episodic ataxia type 2 with no response to acetazolamide or 4-aminopyridine
• A novel pathogenic CACNA1A variant causing episodic ataxia type 2 (EA2) spectrum phenotype in four family members and a novel combined therapy
• A sleep modulated Channelopathy: a novel CACNA1A pathogenic variant identified in episodic Ataxia type 2 and a potential link to sleep alleviated migraine
• A step forward for stress-induced ataxia
• Aberrant cerebellar Purkinje cell activity as the cause of motor attacks in a mouse model of episodic ataxia type 2
• Altered brain state during episodic dystonia in tottering mice decouples primary motor cortex from limb kinematics
• Aminopiridines in the treatment of multiple sclerosis and other neurological disorders
• Aminopyridines and Acetyl-DL-leucine: New Therapies in Cerebellar Disorders
• Analysis of Fibroblast Growth Factor 14 (FGF14) structural variants reveals the genetic basis of the early onset nystagmus locus NYS4 and variable ataxia
• Association of A Novel Splice Site Mutation in P/Q-Type Calcium Channels with Childhood Epilepsy and Late-Onset Slowly Progressive Non-Episodic Cerebellar Ataxia
• CACNA1A variant associated with generalized dystonia
• Case report and ten-year follow-up of episodic ataxia type 2 due to a novel variant in CACNA1A
• Case Report: A Novel CACNA1A Mutation Caused Flunarizine-Responsive Type 2 Episodic Ataxia and Hemiplegic Migraine With Abnormal MRI of Cerebral White Matter
• Cerebral Superficial Siderosis : Etiology, Neuroradiological Features and Clinical Findings
• Characterization of the dominant inheritance mechanism of Episodic Ataxia type 2
• Chronic lymphocytic inflammation with pontine perivascular enhancement responsive to steroids, a mimicker of malignancy: a case report and review of the literature
• Clinical and genetic characterization of CACNA1A-related disease
• Clinical characteristics of patients with dizziness/vertigo showing a dissociation between caloric and video head impulse test results
• Clinical features and <em>CACNA1A</em> gene mutation in a family with episodic ataxia type 2
• Clinical features and CACNA1A gene mutation in a family with episodic ataxia type 2
• Cognitive deficits in episodic ataxia type 2 mouse models
• Coincidental occurance of episodic ataxia and multiple sclerosis: a case report and review of the literature
• Comprehensive systematic review summary: Treatment of cerebellar motor dysfunction and ataxia: Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology
• Corrective and preventive actions (CAPAs) in eye bank
• Deconstructing speech alterations in episodic ataxia type 2: Perceptual-acoustic analysis in a case due to CACNA1A gene mutation
• Developing a pathway to clinical trials for <em>CACNA1A</em>-related epilepsies: A patient organization perspective
• Differentiating episodic ataxia type 2 from migraine: a case report
• Diversity of CACNA1A-related disorders
• Downbeat Nystagmus in Episodic Ataxia Type 1 Associated with a Novel KCNA1 Mutation
• Efficacy of levetiracetam in patients with episodic ataxia type 2 caused by CACNA1A mutation: three case reports
• Electrophysiological Studies Support Utility of Positive Modulators of SK Channels for the Treatment of Spinocerebellar Ataxia Type 2
• Endocannabinoid dysfunction in neurological disease: neuro-ocular DAGLA-related syndrome
• Epidemiology of Cerebellar Diseases and Therapeutic Approaches
• Epilepsy and episodic ataxia type 2: family study and review of the literature
• Episodic ataxia type 2 (EA2) with interictal myokymia and focal dystonia
• Episodic ataxia type 2 characterised by recurrent dizziness/vertigo: a report of four cases
• Episodic ataxia type 2 with a novel missense variant (Leu602Arg) in CACNA1A
• Episodic ataxia type 2: a clinical, genetic and radiological study of 10 patients
• Episodic ataxias in children and adolescents: Clinical findings and suggested diagnostic criteria
• Fampridine and Acetazolamide in EA2 and Related Familial EA: A Prospective Randomized Placebo-Controlled Trial
• Frequency and phenotypic spectrum of spinocerebellar ataxia 27B and other genetic ataxias in a Spanish cohort of late-onset cerebellar ataxia
• From Genotype to Phenotype: Expanding the Clinical Spectrum of <em>CACNA1A</em> Variants in the Era of Next Generation Sequencing
• Functional consequences of SLC1A3 mutations associated with episodic ataxia 6
• Gabapentin Relieves Vertigo of Periodic Vestibulocerebellar Ataxia: 3 Cases and Possible Mechanism
• Generation of induced pluripotent stem cell lines carrying monoallelic (UCSFi001-A-60) or biallelic (UCSFi001-A-61; UCSFi001-A-62) frameshift variants in CACNA1A using CRISPR/Cas9
• Hashimoto's encephalopathy presenting with isolated cerebellar ataxia in 13 children
• Hemiplegic migraine type 2 caused by a novel variant within the P-type ATPase motif in ATP1A2 concomitant with a CACNA1A variant
• Impact of 4-aminopyridine on vestibulo-ocular reflex performance
• Inherited episodic ataxia type 2 in pregnancy: A case report
• Instrumented gait analysis defines the walking signature of CACNA1A disorders
• Major intra-familial phenotypic heterogeneity and incomplete penetrance due to a CACNA1A pathogenic variant
• Mechanism of stress-induced attacks in an episodic neurologic disorder
• Mutations in the Voltage Dependent Calcium Channel <em>CACNA1A</em> (P/Q type alpha 1A subunit) Causing Neurological Disorders - An Overview
• New Nonsense Variant c.2983G&gt;T; p.Glu995* in the CACNA1A Gene Causes Progressive Autosomal Dominant Ataxia
• Novel Genetic Variants Expand the Functional, Molecular, and Pathological Diversity of <em>KCNA1</em> Channelopathy
• Novel Mutation in <em>CACNA1A</em> Associated with Activity-Induced Dystonia, Cervical Dystonia, and Mild Ataxia
• Novel mutation in exon11 of <em>PRKCG</em> (SCA14): A case report
• Paraneoplastic Progressive Downbeat Nystagmus, Ataxia and Sensorineural Hearing Loss due to the ANTI-Kelch-11 Protein Antibody
• Paroxysmal movement disorders - practical update on diagnosis and management
• Pharmacotherapy of cerebellar and vestibular disorders
• Pharmacotherapy of Vestibular Disorders, Nystagmus and Cerebellar Disorders
• Phenotypes, genotypes, and the management of paroxysmal movement disorders
• Phenotypic Characterization of Larval Zebrafish (Danio rerio) with Partial Knockdown of the cacna1a Gene
• Single-fiber electromyography-based diagnosis of CACNA1A mutation in children: A potential role of the electrodiagnosis in the era of whole exome sequencing
• Slowed abduction during smooth pursuit eye movement in episodic ataxia type 2 with a novel CACNA1A mutation
• Targeting Alternative Splicing as a Potential Therapy for Episodic Ataxia Type 2
• The complexities of CACNA1A in clinical neurogenetics
• The efficacy of combining topiramate and 4-aminopyridine to reduce relapses and interictal progression in two cases of episodic ataxia type 2
• The electrophysiological footprint of CACNA1A disorders
• The expanding spectrum of paroxysmal movement disorders: update from clinical features to therapeutics
• The neurological update: therapies for cerebellar ataxias in 2020
• The neuropsychiatric phenotype in CACNA1A mutations: a retrospective single center study and review of the literature
• Therapeutic Potential of Sodium Channel Blockers as a Targeted Therapy Approach in <em>KCNA1</em>-Associated Episodic Ataxia and a Comprehensive Review of the Literature
• Therapy of episodic ataxias: case report and review of the literature
• Transient Neurological Symptoms Preceding Cerebellar Ataxia with Glutamic Acid Decarboxylase Antibodies
• Treatable Ataxias: How to Find the Needle in the Haystack?
• Treatment of dizziness: an interdisciplinary update
• Two Children with Early-Onset Strokes and Intractable Epilepsy, Both with <em>CACNA1A</em> Mutations
• Two distinct phenotypes, hemiplegic migraine and episodic Ataxia type 2, caused by a novel common CACNA1A variant
• Update on diagnosis and differential diagnosis of vestibular migraine
• Use of Dalfampridine in a Young Child with Episodic Ataxia Type 2
• Vertical Saccadic Slowing in Episodic Ataxia Type 2
• Vestibular impairments in episodic ataxia type 2
• Vestibular Migraine: How to Sort it Out and What to Do About it
• Video head impulse testing in patients with isolated (hemi)nodular infarction
• Wernicke Encephalopathy
• Wernicke Encephalopathy (Nursing)
• What Is Behind Cerebellar Vertigo and Dizziness?
• Whole-Exome Sequencing Implicates <em>SCN2A</em> in Episodic Ataxia, but Multiple Ion Channel Variants May Contribute to Phenotypic Complexity
• Zebrafish as a Model System for the Study of Severe Ca_V2.1 (α_1A) Channelopathies